Incremental prognostic value of the fibrinogen−to−albumin ratio for adverse perinatal outcomes in preeclampsia: a dual−center retrospective cohort study - Scorecard - MDSpire
Advertisement
Incremental prognostic value of the fibrinogen−to−albumin ratio for adverse perinatal outcomes in preeclampsia: a dual−center retrospective cohort study
Clinical Scorecard: Enhanced Prognostic Significance of the Fibrinogen-to-Albumin Ratio for Identifying Adverse Perinatal Outcomes in Preeclampsia: Findings from a Dual-Center Retrospective Study
At a Glance
Category
Detail
Condition
Key Mechanisms
Fibrinogen-to-albumin ratio (FAR) as a prognostic marker for adverse perinatal outcomes, linked to coagulopathy and systemic inflammation.
Target Population
Care Setting
Key Highlights
FAR provides incremental prognostic value for predicting composite adverse perinatal outcomes (CAPO) and informs anesthesia decisions.
Guideline-Based Recommendations
Diagnosis
Management
Consider FAR for risk stratification and monitoring in preeclamptic patients, with specific protocols for implementation.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
FAR can guide anesthesia-relevant decisions and perioperative care, as well as inform overall management strategies.
Clinical Best Practices
Incorporate FAR into existing models for improved prognostic accuracy, with examples of practical application in clinical settings.
